This site is intended for U.S. Healthcare Professionals only.

Phase 3 clinical data—
Study design

cIAI Phase 3 clinical trial vs meropenem

STUDY DESIGN1

Phase 3 study design for Avycaz in cIAI
  • The mMITT population included a subset of patients (n=111) with infections caused by ceftazidime-nonsusceptible Gram-negative pathogens, and a subset of patients (n=105) with infections caused by certain ESBL groups (TEM-1, SHV-12, CTX-M-15, OXA-48) and AmpC that were expected to be inhibited by avibactam1

ESBL, extended-spectrum ß-lactamase.

IV, intravenous.